iBio (IBIO) awards CFO 179,000 stock options vesting to 2036

Rhea-AI Filing Summary

iBio, Inc. reported that its Chief Financial Officer, Felipe Duran, received a grant of stock options covering 179,000 shares of common stock on January 28, 2026 at an exercise price of $2.23 per share. All 179,000 options were reported as directly owned after the grant.

The options vest over time. 25% of the underlying shares will vest on the one-year anniversary of the grant date, and the remaining options will vest in equal quarterly installments over the following 36 months, as long as Duran remains employed by iBio. The options become exercisable starting January 28, 2027 and are scheduled to expire on January 27, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duran Felipe

(Last) (First) (Middle)

C/O IBIO, INC.,

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$2.23	01/28/2026		A		179,000		01/28/2027	01/27/2036	Common Stock	179,000	$0	179,000	D

Explanation of Responses:

1. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

	/s/ Felipe Duran	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did iBio (IBIO) disclose about CFO Felipe Durans stock options?

iBio disclosed a stock option grant to CFO Felipe Duran for 179,000 shares of common stock at a $2.23 exercise price. The options vest over four years and are exercisable starting January 28, 2027, with an expiration date of January 27, 2036.

How many iBio (IBIO) stock options were granted to the CFO?

Felipe Duran received stock options on 179,000 shares of iBio common stock. All 179,000 options were reported as directly owned following the transaction, giving him the right to buy shares at a fixed $2.23 exercise price if the options vest and are exercised.

What is the exercise price and term of the iBio (IBIO) CFO option grant?

The CFOs stock options carry a $2.23 exercise price per share and expire on January 27, 2036. They become exercisable beginning January 28, 2027, giving a long-dated incentive aligned with continued service at iBio.

How do the iBio (IBIO) CFO stock options vest over time?

The options vest in stages: 25% of the underlying shares vest on the one-year anniversary of the January 28, 2026 grant date. The remaining 75% then vest in equal quarterly installments over 36 months, contingent on Felipe Duran remaining employed by iBio.

Is the iBio (IBIO) CFO option grant a purchase or a cost-free award?

The filing shows the stock options were granted at a derivative security price of $0, indicating no upfront purchase cost to the CFO. However, any future share acquisition requires paying the $2.23 per share exercise price if and when vested options are exercised.

What ownership form is reported for the iBio (IBIO) CFO stock options?

The 179,000 stock options granted to CFO Felipe Duran are reported as directly owned. The filing does not attribute them to any trust, partnership, or other entity, meaning they are listed as directly held derivative securities in his name.